Asia
Allergan and its development partner Sosei Group have voluntarily suspended clinical trials of HTL0018318 in Alzheimer’s and other types of dementia because of safety problems.
Novo Nordisk is laying off 400 staffers so it can shift funds toward biological and technological innovation.
Patients with advanced esophageal squamous cell carcinoma with higher PD-L1 expression can benefit better from leading PD-1 antibody drugs
Researchers at Kanazawa University report in Scientific Reports how a particular biochemical signaling pathway cancels biological noise, ensuring the proper stem cell differentiation during development.
System will be Installed at Shonan Kamakura Advanced Medical Center, Scheduled to be Complete in September 2020
Without a doubt China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates. And it seems that western pharmaceutical companies are making greater inroads there.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
One day after it was revealed Takeda is moving its U.S. headquarters from Illinois to Boston ahead of the completion of the Shire Plc acquisition, the Japanese company is reportedly considering the sale of Shire’s eye-care business in order to cut some debt incurred from funding the $62 billion deal.
WuXi AppTec congratulates its partner Hutchison MediPharma (HMP) on receiving approval of fruquintinib capsules (Elunate®) for metastatic colorectal cancer from the National Medical Products Administration of China
FMX101 Demonstrated Highly Statistically Significant Improvement Compared with Vehicle in Both Co-Primary Efficacy Endpoints
PRESS RELEASES